Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivalis has signed a research license agreement with Mymetics, a Swiss company that develops a new generation of mucosal- and virosome-based vaccines.
Subscribe to our email newsletter
The agreement was signed by the companies to evaluate the replication of an undisclosed virus in Vivalis’ EB66 cell line for the manufacturing of human vaccines developed by Mymetics.
The EB66 cell line, derived from avian embryonic stem cells, replicate a wide range of human and animal viruses and are currently used for the production of investigational viral vaccines by many major vaccine developers.
Vivalis co-managers, CEO Franck Grimaud and CSO Majid Mehtali said that they were pleased to have another organisation evaluating their EB66 cell line.
“This agreement brings the number of worldwide, new research and commercial licenses to the EB66 cell line up to four in 2010,” Grimaud and Mehtali said.
Vivalis provides cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs.